XOMA Royalty (NASDAQ:XOMA) Stock Crosses Above Two Hundred Day Moving Average – What’s Next?

XOMA Royalty Corporation (NASDAQ:XOMA)’s share price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $30.08 and traded as high as $40.15. XOMA Royalty shares last traded at $39.37, with a volume of 150,528 shares changing hands.

Analysts Set New Price Targets

Several brokerages have recently issued reports on XOMA. TD Cowen raised shares of XOMA Royalty to a “hold” rating in a research note on Friday, February 13th. Zacks Research raised shares of XOMA Royalty from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 8th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of XOMA Royalty in a research note on Monday, December 29th. Leerink Partners reaffirmed an “outperform” rating on shares of XOMA Royalty in a research note on Tuesday, February 24th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $97.00 price objective on shares of XOMA Royalty in a research note on Friday, March 20th. Three analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $68.25.

XOMA Royalty Stock Performance

The firm’s fifty day simple moving average is $30.75 and its 200 day simple moving average is $30.14. The company has a market capitalization of $451.77 million, a price-to-earnings ratio of 25.96 and a beta of 0.68. The company has a debt-to-equity ratio of 1.15, a current ratio of 3.37 and a quick ratio of 3.37.

XOMA Royalty (NASDAQ:XOMA) last announced its earnings results on Wednesday, March 18th. The biotechnology company reported $0.12 EPS for the quarter, topping the consensus estimate of ($0.04) by $0.16. XOMA Royalty had a net margin of 45.75% and a return on equity of 10.32%. The company had revenue of $13.76 million during the quarter, compared to analysts’ expectations of $11.13 million. On average, sell-side analysts forecast that XOMA Royalty Corporation will post 0.94 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. boosted its holdings in shares of XOMA Royalty by 13.9% during the second quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 543 shares during the period. Russell Investments Group Ltd. boosted its holdings in shares of XOMA Royalty by 3,436.4% during the third quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 756 shares during the period. State of Alaska Department of Revenue acquired a new stake in shares of XOMA Royalty during the fourth quarter worth approximately $27,000. Dimensional Fund Advisors LP boosted its holdings in shares of XOMA Royalty by 4.5% during the third quarter. Dimensional Fund Advisors LP now owns 29,190 shares of the biotechnology company’s stock worth $1,124,000 after purchasing an additional 1,269 shares during the period. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of XOMA Royalty by 203.1% during the second quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 1,523 shares during the period. 95.92% of the stock is currently owned by institutional investors and hedge funds.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.